<?xml version="1.0" encoding="UTF-8" ?>

<Genomics_ConceptTask>
<TEXT><![CDATA[Splicing factor SF3B1 promotes endometrial cancer progression via regulating 
KSR2 RNA maturation.

Although endometrial cancer is the most common cancer of the female reproductive 
tract, we have little understanding of what controls endometrial cancer beyond 
the transcriptional effects of steroid hormones such as estrogen. As a result, 
we have limited therapeutic options for the ~62,000 women diagnosed with 
endometrial cancer each year in the United States. Here, in an attempt to 
identify new prognostic and therapeutic targets, we focused on a new area for 
this cancer-alternative mRNA splicing-and investigated whether splicing factor, 
SF3B1, plays an important role in endometrial cancer pathogenesis. Using a 
tissue microarray, we found that human endometrial tumors expressed more SF3B1 
protein than non-cancerous tissues. Furthermore, SF3B1 knockdown reduced in 
vitro proliferation, migration, and invasion of the endometrial cancer cell 
lines Ishikawa and AN3CA. Similarly, the SF3B1 inhibitor, Pladienolide-B 
(PLAD-B), reduced the Ishikawa and AN3CA cell proliferation and invasion in 
vitro. Moreover, PLAD-B reduced tumor growth in an orthotopic endometrial cancer 
mouse model. Using RNA-Seq approach, we identified ~2000 differentially 
expressed genes (DEGs) with SF3B1 knockdown in endometrial cancer cells. 
Additionally, alternative splicing (AS) events analysis revealed that SF3B1 
depletion led to alteration in multiple categories of AS events including 
alternative exon skipping (ES), transcript start site usage (TSS), and 
transcript termination site (TTS) usage. Subsequently, bioinformatics analysis 
showed KSR2 as a potential candidate for SF3B1-mediated functions in endometrial 
cancer. Specifically, loss of SF3B1 led to decrease in KSR2 expression, owing to 
reduced maturation of KSR2 pre-mRNA to a mature RNA. Importantly, we found 
rescuing the KSR2 expression with SF3B1 knockdown partially restored the cell 
growth of endometrial cancer cells. Taken together, our data suggest that SF3B1 
plays a crucial oncogenic role in the tumorigenesis of endometrial cancer and 
hence may support the development of SF3B1 inhibitors to treat this disease.]]></TEXT>
<TAGS>
<PERTURBING_ACTION id="P0" spans="856~871" text="SF3B1 knockdown" perturbingaction="rnai/knockdown" />
<PERTURBING_ACTION id="P1" spans="1002~1043" text="SF3B1 inhibitor, Pladienolide-B  (PLAD-B)" perturbingaction="pharmacological inhibition" />
<PERTURBING_ACTION id="P2" spans="1295~1310" text="SF3B1 knockdown" perturbingaction="rnai/knockdown" />
<PERTURBING_ACTION id="P3" spans="1411~1427" text="SF3B1  depletion" perturbingaction="gene loss-of-function" />
<PERTURBING_ACTION id="P4" spans="1749~1762" text="loss of SF3B1" perturbingaction="gene loss-of-function" />
<PERTURBING_ACTION id="P5" spans="1919~1934" text="SF3B1 knockdown" perturbingaction="rnai/knockdown" />
<PERTURBING_ACTION id="P6" spans="1885~1913" text="rescuing the KSR2 expression" perturbingaction="gene gain-of-function" />
<CONTEXT id="C0" spans="880~889" text="in  vitro" context="in vitro" />
<CONTEXT id="C1" spans="936~985" text="endometrial cancer cell  lines Ishikawa and AN3CA" context="transformed cells" />
<CONTEXT id="C2" spans="1057~1080" text="Ishikawa and AN3CA cell" context="transformed cells" />
<CONTEXT id="C3" spans="1108~1117" text="in  vitro" context="in vitro" />
<CONTEXT id="C4" spans="1163~1205" text="orthotopic endometrial cancer  mouse model" context="organism" />
<CONTEXT id="C5" spans="1314~1338" text="endometrial cancer cells" context="transformed cells" />
<CONTEXT id="C6" spans="1974~1998" text="endometrial cancer cells" context="transformed cells" />
<PHENOTYPE id="PH0" spans="890~903" text="proliferation" phenotype="proliferation" />
<PHENOTYPE id="PH1" spans="905~914" text="migration" phenotype="migration" />
<PHENOTYPE id="PH2" spans="920~928" text="invasion" phenotype="invasion" />
<PHENOTYPE id="PH3" spans="1081~1094" text="proliferation" phenotype="proliferation" />
<PHENOTYPE id="PH4" spans="1099~1107" text="invasion" phenotype="invasion" />
<PHENOTYPE id="PH5" spans="1144~1156" text="tumor growth" phenotype="tumour growth" />
<PHENOTYPE id="PH6" spans="1958~1970" text="cell  growth" phenotype="cell growth" />
<EFFECT id="E0" spans="872~879" text="reduced" effect="negative" />
<EFFECT id="E1" spans="1045~1052" text="reduced" effect="negative" />
<EFFECT id="E2" spans="1136~1143" text="reduced" effect="negative" />
<EFFECT id="E3" spans="1935~1953" text="partially restored" effect="rescues" />
<ENTITY_LINKING id="EN0" perturbing_actionID="P0" perturbing_actionText="SF3B1 knockdown" effectID="E0" effectText="reduced" contextID="C0" contextText="in  vitro" phenotypeID="PH0" phenotypeText="proliferation" />
<ENTITY_LINKING id="EN1" perturbing_actionID="P0" perturbing_actionText="SF3B1 knockdown" effectID="E0" effectText="reduced" contextID="C0" contextText="in  vitro" phenotypeID="PH1" phenotypeText="migration" />
<ENTITY_LINKING id="EN2" perturbing_actionID="P0" perturbing_actionText="SF3B1 knockdown" effectID="E0" effectText="reduced" contextID="C0" contextText="in  vitro" phenotypeID="PH2" phenotypeText="invasion" />
<ENTITY_LINKING id="EN3" perturbing_actionID="P0" perturbing_actionText="SF3B1 knockdown" effectID="E0" effectText="reduced" contextID="C1" contextText="endometrial cancer cell  lines Ishikawa and AN3CA" phenotypeID="PH0" phenotypeText="proliferation" />
<ENTITY_LINKING id="EN4" perturbing_actionID="P0" perturbing_actionText="SF3B1 knockdown" effectID="E0" effectText="reduced" contextID="C1" contextText="endometrial cancer cell  lines Ishikawa and AN3CA" phenotypeID="PH1" phenotypeText="migration" />
<ENTITY_LINKING id="EN5" perturbing_actionID="P0" perturbing_actionText="SF3B1 knockdown" effectID="E0" effectText="reduced" contextID="C1" contextText="endometrial cancer cell  lines Ishikawa and AN3CA" phenotypeID="PH2" phenotypeText="invasion" />
<ENTITY_LINKING id="EN6" perturbing_actionID="P1" perturbing_actionText="SF3B1 inhibitor, Pladienolide-B  (PLAD-B)" effectID="E1" effectText="reduced" contextID="C2" contextText="Ishikawa and AN3CA cell" phenotypeID="PH3" phenotypeText="proliferation" />
<ENTITY_LINKING id="EN7" perturbing_actionID="P1" perturbing_actionText="SF3B1 inhibitor, Pladienolide-B  (PLAD-B)" effectID="E1" effectText="reduced" contextID="C2" contextText="Ishikawa and AN3CA cell" phenotypeID="PH4" phenotypeText="invasion" />
<ENTITY_LINKING id="EN8" perturbing_actionID="P1" perturbing_actionText="SF3B1 inhibitor, Pladienolide-B  (PLAD-B)" contextID="C3" contextText="in  vitro" effectID="E1" effectText="reduced" phenotypeID="PH3" phenotypeText="proliferation" />
<ENTITY_LINKING id="EN9" perturbing_actionID="P1" perturbing_actionText="SF3B1 inhibitor, Pladienolide-B  (PLAD-B)" effectID="E1" effectText="reduced" phenotypeID="PH4" phenotypeText="invasion" contextID="C3" contextText="in  vitro" />
<ENTITY_LINKING id="EN10" perturbing_actionID="P6" perturbing_actionText="rescuing the KSR2 expression" effectID="E3" effectText="partially restored" phenotypeID="PH6" phenotypeText="cell  growth" contextID="C6" contextText="endometrial cancer cells" />
</TAGS>
</Genomics_ConceptTask>